LAS VEGAS, Aug. 24, 2009 (GLOBE NEWSWIRE) -- At times, breast cancer awareness initiatives seem almost ubiquitous, a pink parade of celebrities and marketing inviting the public to understand and support the cause. Yet oddly enough, there seems to be a scarcity of medical device assets at the critical intersection of women's health care and oncology. In fact, we are not currently aware of any other publicly traded companies other than SenoRx Inc. (Nasdaq:SENO) that are exclusively focused on breast cancer intervention, one of the top killers of women. With considerable product successes already, SenoRx's penetration thus far may well be likened to the proverbial first strike in an oil field of mass proportions.
SenoRx is a medical device company that develops, manufactures, and sells minimally invasive devices for the diagnosis and treatment of breast cancer and is a rapidly growing participant in the medical device market that includes Endologix, Inc. (Nasdaq:ELGX), Micrus Endovascular Corporation (Nasdaq:MEND), Vascular Solutions, Inc. (Nasdaq:VASC), Solta Medical, Inc. (Nasdaq:SLTM), and Volcano Corporation (Nasdaq:VOLC). A report featuring SenoRx is available at: www.IntegrityIR.com/SENO
The lack of companies dedicated to diagnose and treat women's breast cancer extends beyond public companies. In fact, there are only a handful of late-stage private companies either in breast cancer diagnosis or treatment and there is a dearth of small cap public companies in women's health in general, save a few single-product companies focused on gynecological concerns. Moreover, there also seems to be little activity outside the United States in the aforementioned arena.
Certainly, there are large companies which possess women's health or oncology franchises. SenoRx does not own the space despite its successes thus far. Although data confirms that women's health care and oncology are two of the fastest growing medical treatment market segments, we have not seen the larger companies display a proven ability to sustain innovation. To the contrary, in past cycles it has been the smaller companies like SenoRx that are the true innovators, and which are then bought-out by the larger medical device aggregators. For example, VNUS Medical Technologies, Inc., formerly a publicly traded company on the NASDAQ in the medical device space, was recently acquired in June 2009.
SenoRx's success extends well beyond the uniqueness of its placement at the crossroads of women's health care and oncology.
